Pembrolizumab + axitinib

Pembrolizumab and axitinib at a glance

Pembrolizumab, commonly known as Keytruda, is an immunotherapy medicine. Axitinib, commonly known as Inlyta, is a targeted therapy supplied as tablets. The combination does not contain conventional chemotherapy. Both medicines can affect healthy organs as well as cancer, so regular checks are part of treatment.

This is an established first treatment option for appropriate adults with advanced renal cell carcinoma, the main group of kidney cancers. It is not the same regimen as pembrolizumab given alone after kidney-cancer surgery.

Treatment combines hospital appointments with axitinib taken at home each day. The team adjusts care to your response and side effects. Reporting symptoms helps them support you; it does not automatically mean both medicines must stop permanently.

How the combination works

Pembrolizumab blocks PD-1, a protein involved in regulating immune-cell activity. This may help immune cells recognise and attack cancer. It can also allow inflammation in healthy tissues, explaining why new symptoms sometimes need assessment even when they seem unrelated to cancer.

Axitinib blocks signals through vascular endothelial growth factor receptors, often shortened to VEGF receptors. These signals help blood vessels grow. Interrupting them can reduce the blood supply supporting a tumour. Effects on normal blood vessels also help explain blood-pressure and healing problems.

These approaches work together, but benefit differs between people. Ask what the treatment aims to achieve for you, when scans will assess it, and how preserving your daily activities will influence decisions.

How the team decides whether it is suitable

The oncologist considers the cancer subtype, previous treatment, symptoms and overall health. The key combination trial included advanced kidney cancers with a clear-cell component. A positive PD-L1 test is not required by the US indication for this pair. Other kidney-cancer subtypes or previous immunotherapy require an individual specialist discussion.

Tell the team about autoimmune illnesses, an organ transplant, a previous donor stem-cell transplant and serious reactions to earlier immunotherapy. These can change the balance of benefit and risk. A history of liver disease, heart problems, stroke, blood clots or poorly controlled blood pressure also matters.

Availability and treatment criteria differ between countries and hospitals. International references support this information but do not confirm Indian approval, supply or funding for your situation.

Before treatment starts

Baseline checks usually include blood counts, kidney and liver function, thyroid hormones, glucose and blood salts. Blood pressure and urine protein are also assessed. Blood pressure should be well controlled before axitinib starts. Further heart tests or infection screening depend on your history and hospital policy.

Tell the team about recent bleeding, bowel problems, wounds that have not healed, planned operations or dental procedures, and pregnancy or breastfeeding. Bring all medicines and supplements, including photographs of packets if the names are uncertain.

Ask for a demonstration if you will check blood pressure at home. Write down your normal bowel pattern and any existing skin or breathing symptoms, so changes are easier to describe. Before the first dose, know whom to call overnight and whether another person can help with tablets, transport or recording readings.

How treatment is taken or given

Pembrolizumab appointments

A usual adult intravenous schedule is 200 mg every three weeks or 400 mg every six weeks, infused over about 30 minutes. Assessment and preparation make the whole appointment longer. These are examples; follow your hospital's prescription.

Some services use a formulation injected under the skin. Its dose and administration instructions differ from the intravenous product, and the products must not be interchanged by copying doses. Your hospital will explain the formulation available to you.

Tell the nurse immediately about shivering, flushing, itching, dizziness, wheezing, swelling or sudden pain during administration. Reactions can also begin after leaving hospital; contact the team promptly if they do.

Axitinib tablets at home

The usual starting dose is 5 mg twice daily, about 12 hours apart, with or without food. Swallow tablets whole with water; do not crush or chew them. Your prescribed dose may differ or change. Check the strength and number of tablets each time the pharmacy supplies them.

Axitinib is usually continuous, including days without a pembrolizumab appointment, unless your team tells you to pause. A morning-and-evening reminder can help. Mark each dose after taking it, especially if relatives share responsibility for your medicines.

Missed doses and vomiting

If you miss an axitinib dose or vomit after taking it, do not take a replacement or double dose. Take the next prescribed dose at its usual time. Contact the team for repeated vomiting or uncertainty about what you have taken.

Store tablets in their original packaging as directed, away from children. Ask the pharmacist about safe handling and disposal. If swallowing becomes difficult, obtain advice instead of altering tablets yourself.

Monitoring and checking response

Blood pressure may rise without symptoms. Early checks and a home record can identify this before you feel unwell. Ask for your own calling thresholds and the timetable for blood and urine tests. Blood counts, liver and kidney function, thyroid hormones and glucose are monitored throughout treatment.

Liver monitoring is particularly important: pembrolizumab with axitinib can cause more frequent severe liver-enzyme increases than expected with either medicine alone. Both medicines may need interruption while the team investigates.

Scans, symptoms and examination together show whether treatment is helping. The team may reduce, increase or pause axitinib. Pembrolizumab is delayed or stopped for significant toxicity rather than managed by lowering its dose. Do not change either treatment yourself.

At appointments, describe what symptoms prevent you doing: walking to the bathroom, preparing food or sleeping comfortably. This is often more useful than saying a side effect is merely “bad”. Keep questions and recent readings together so they are easy to review.

Common side effects and practical care

More commonly reported effects: how to read this section

The following groups were each reported in at least 20% of people receiving this combination in the KEYNOTE-426 safety data: diarrhoea, fatigue, high blood pressure, liver effects, low thyroid function, reduced appetite, nausea, sore mouth, hand-foot skin problems, rash, hoarseness, cough and constipation. Frequencies describe a study population, not your individual risk. “Common” does not mean mild, and the next section is not a list of effects that are all rare.

Diarrhoea and bowel changes

Record the number of loose stools and how this differs from normal. Contact your team promptly about new or worsening diarrhoea, including waking at night to pass stool. Axitinib can upset the bowel, but pembrolizumab can cause inflammation called colitis; infection is another possibility. Do not decide the cause yourself or wait several days for it to settle.

While seeking advice, take regular sips of fluid unless you have a fluid restriction. Small, simple meals may be easier. Ask about oral rehydration if losses are substantial. Use anti-diarrhoea medicine only according to the plan agreed with your team. Blood or mucus, worsening pain, dizziness or reduced urine need especially prompt assessment. Diet changes alone do not treat immune colitis.

Tiredness and reduced stamina

Fatigue may feel different from ordinary tiredness and may not disappear after sleep. Plan important tasks for your better hours, divide larger jobs into stages and alternate manageable activity with rest. A short walk may be helpful if you feel steady and well enough. Accept practical help without feeling you must remain in bed all day.

Tell the team when fatigue interferes with washing, dressing or eating. A sudden change, faintness or marked weakness needs prompt advice. Anaemia, poor sleep, dehydration, thyroid changes and other hormone problems can contribute; they require different treatment.

High blood pressure

You may feel completely normal despite a high reading. Measure as instructed, record the result and follow your team's calling limits. They may start or adjust blood-pressure medicine and occasionally pause axitinib. Do not stop a prescribed blood-pressure tablet simply because a reading has improved. Report headaches or visual changes promptly, and use the emergency guidance below for severe symptoms.

Nausea, low appetite and weight change

Use prescribed anti-sickness medicine as instructed. Eat small amounts more often and choose foods that are comfortable to smell and swallow. If hot cooking smells worsen nausea, cooler food may be easier. Repeated vomiting, inability to keep drinks down or persistent symptoms despite medicine need contact with the team. Do not take extra axitinib after vomiting.

When appetite is poor, make small meals nourishing with protein and energy sources you tolerate. There is no special food that makes this combination work better. Tell the team about weight loss, and request dietitian support early instead of waiting until eating becomes very difficult. Dietary advice should take kidney function and any other restrictions into account.

Sore mouth and altered taste

Check your mouth for sore areas and keep teeth and dentures gently clean. Use a soft toothbrush and mouth-rinsing advice from your team. Soft, moist food may be more comfortable; very hot, spicy or acidic foods can aggravate soreness. Report ulcers, painful swallowing, white patches or difficulty drinking. Pain relief or treatment for an infection may help you eat more comfortably.

If familiar foods taste unpleasant, try alternative flavours or textures without forcing large meals. Taste change itself should not lead to stopping food or fluids. Ask for help when mouth symptoms and low appetite occur together.

Hands, feet and other skin changes

Palms and soles can become tender, swollen, thickened or cracked. Changes may look red on lighter skin and darker on brown or black skin. Moisturise gently with a product recommended by the team, wear comfortable shoes, and reduce rubbing, pressure and hot-water exposure. Tell the team early about painful areas, particularly broken skin or difficulty walking or gripping objects.

Report itching or a new rash. Gentle cleansers, unperfumed moisturisers, sun protection and loose clothing may help minor irritation after the team has assessed it. Do not apply several new creams at once. A painful, blistering or peeling rash, especially with mouth or eye sores, needs immediate assessment.

Constipation, cough and a changed voice

Tell the team if stools become hard or difficult to pass. Fluids, gentle movement and suitable food changes can help, but ask before using laxatives, enemas or suppositories. Severe abdominal pain, vomiting or inability to pass gas requires assessment rather than simply adding fibre.

A hoarse or weaker voice can occur. Resting your voice and avoiding smoke may help; report persistent or worsening changes. A new cough also needs prompt advice, because cough can indicate lung inflammation or infection. Difficulty swallowing, breathlessness or marked muscle weakness should not be attributed to simple hoarseness.

Thyroid and liver changes

An underactive thyroid can cause feeling unusually cold, constipation, low mood or slowing down. Blood tests help distinguish this from other reasons for fatigue. The team may prescribe thyroid replacement; do not take iodine or “thyroid support” products yourself.

Liver changes often appear on tests before symptoms. Do not skip checks because you feel well. Yellow eyes or skin, dark urine, right-sided upper abdominal pain, marked nausea or unexplained bruising need prompt contact. Liver effects in this combination deserve attention even though they are in the more commonly reported group.

Important side effects to recognise

Immune inflammation and other effects

These problems vary in frequency and severity. They are grouped by what you need to recognise, without giving unsupported “common”, “less common” or “rare” labels for the whole combination. Pembrolizumab can inflame healthy organs during treatment or after it has ended. A previous uncomplicated dose does not exclude a later reaction.

New cough or breathlessness can reflect lung inflammation. Persistent diarrhoea or abdominal pain can reflect bowel inflammation. Hormone-gland effects can cause severe tiredness, dizziness, persistent headache, heat or cold intolerance, or unexpected weight change. Excessive thirst and frequent urination can indicate diabetes; vomiting, deep breathing or confusion alongside these symptoms need emergency assessment. Some hormone problems need continuing replacement treatment.

Inflammation can also affect the heart, muscles, nerves, eyes or kidneys. Report a racing or irregular heartbeat, new weakness, numbness, eye pain or vision change. Marked muscle weakness, drooping eyelids or difficulty swallowing need immediate advice; use emergency services if breathing or swallowing is affected.

The team may pause treatment, investigate the cause and prescribe steroids or other medicines. Follow the steroid dose and gradual reduction plan exactly. Taking prescribed steroids for an immune reaction is part of treatment; do not avoid them or stop abruptly through concern about “switching off” immunotherapy.

Kidney, circulation and healing problems

Urine protein may be found before symptoms develop. Reduced urine, ankle swelling or blood in urine needs assessment. Kidney problems may also follow dehydration or immune inflammation. Keep drinking within your advised allowance and contact the team when you cannot maintain this.

Axitinib can cause bleeding, blood clots and heart problems. Unexplained bruising, recurrent nosebleeds or a painful swollen limb need prompt advice. Severe bleeding, chest pain or stroke symptoms need emergency care. A new symptom should not be dismissed because a recent blood count was acceptable.

Bowel perforation or a fistula, an abnormal connection between organs, can occur. Severe persistent abdominal pain needs urgent assessment. A rare brain condition called RPLS, also known as PRES, may cause severe headache, confusion, seizures or vision changes. Seek emergency care for these symptoms.

Axitinib can delay healing. Inform the team before surgery or invasive dental treatment. The US prescribing information advises withholding it for at least two days before elective surgery, and at least two weeks after major surgery and until healing is adequate. Your team must plan the dates and authorise restarting.

Other medicines and vaccinations

Ask the oncology pharmacist to check every new prescription, non-prescription medicine and supplement. Include painkillers, blood thinners, herbal or Ayurvedic products, and medicines for infections or seizures. Some medicines substantially raise or lower axitinib levels. Avoid grapefruit, grapefruit juice and St John's wort. Do not stop necessary prescribed medicines without advice.

Check vaccination plans with the team before booking, especially if steroids or other immune-suppressing medicines become necessary. The appropriate vaccine and timing depend on your treatment and health. Carry an up-to-date medicine list to other appointments so clinicians can check interactions before prescribing.

Everyday life during treatment

You may continue work, exercise and family activities as you feel able. Plan around appointments, and allow flexibility when energy varies. Avoid driving if dizziness, fatigue or vision problems make it unsafe. Comfortable footwear and shorter periods of activity can help when the feet are sore.

Ask for help with symptoms, mood, finances or travel before difficulties build up. A caregiver can note changes and help make calls, but your own priorities should remain central. Keep a small record of tablets, bowel changes and blood-pressure readings, without feeling obliged to monitor every sensation continuously.

Use ordinary infection-prevention measures, including handwashing and safe food preparation. Discuss particular exposures or travel with the team. You do not need to assume that all normal contact with family is unsafe.

Fertility, pregnancy and breastfeeding

Discuss future fertility before starting: treatment may affect reproductive function, and any preservation options need timely specialist advice. A change in periods does not establish that pregnancy is impossible. Pregnancy testing is needed before treatment for people who could become pregnant.

Under US product advice, people who could become pregnant should use effective contraception during treatment and until both intervals have passed: four months after the final pembrolizumab dose and one week after the final axitinib dose. Men with partners who could become pregnant should use effective contraception during axitinib treatment and for one week afterwards. The team should confirm locally applicable advice.

Do not breastfeed during treatment. Under US guidance, both stopping intervals must be completed: four months after pembrolizumab and two weeks after axitinib. If axitinib continues after pembrolizumab ends, its precautions continue too. Tell the team immediately about a suspected pregnancy.

After a pause or the end of treatment

Before restarting, confirm which medicine is restarting, its dose and any outstanding tests. An interruption may be temporary, but some reactions require permanent discontinuation. Do not use leftover tablets to restart independently.

Pembrolizumab may have a planned maximum duration, often around two years in advanced kidney-cancer protocols; axitinib may continue separately while helpful and tolerated. The plan is individual and can change earlier because of response or side effects.

Immune effects can begin after pembrolizumab finishes. Keep the alert card and contact details, continue follow-up and report new symptoms. Long-term hormone replacement or other care may remain necessary even after cancer treatment stops.

Frequently asked questions